- Home
- ICCM vs VIGL Comparison
ICCM vs VIGL Comparison
Compare ICCM & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- VIGL
- Stock Information
- Founded
- ICCM 2006
- VIGL 2020
- Country
- ICCM Israel
- VIGL United States
- Employees
- ICCM N/A
- VIGL N/A
- Industry
- ICCM
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- VIGL Health Care
- Exchange
- ICCM Nasdaq
- VIGL Nasdaq
- Market Cap
- ICCM 75.8M
- VIGL 89.3M
- IPO Year
- ICCM N/A
- VIGL 2022
- Fundamental
- Price
- ICCM $1.41
- VIGL $3.03
- Analyst Decision
- ICCM Strong Buy
- VIGL Strong Buy
- Analyst Count
- ICCM 2
- VIGL 5
- Target Price
- ICCM $2.70
- VIGL $21.00
- AVG Volume (30 Days)
- ICCM 379.2K
- VIGL 642.5K
- Earning Date
- ICCM 04-02-2025
- VIGL 03-25-2025
- Dividend Yield
- ICCM N/A
- VIGL N/A
- EPS Growth
- ICCM N/A
- VIGL N/A
- EPS
- ICCM N/A
- VIGL N/A
- Revenue
- ICCM $3,671,000.00
- VIGL N/A
- Revenue This Year
- ICCM $10.03
- VIGL N/A
- Revenue Next Year
- ICCM $62.68
- VIGL N/A
- P/E Ratio
- ICCM N/A
- VIGL N/A
- Revenue Growth
- ICCM 26.02
- VIGL N/A
- 52 Week Low
- ICCM $0.48
- VIGL $1.49
- 52 Week High
- ICCM $1.66
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- ICCM 60.09
- VIGL 77.87
- Support Level
- ICCM $1.22
- VIGL $2.71
- Resistance Level
- ICCM $1.66
- VIGL $2.95
- Average True Range (ATR)
- ICCM 0.09
- VIGL 0.21
- MACD
- ICCM 0.01
- VIGL 0.03
- Stochastic Oscillator
- ICCM 43.18
- VIGL 86.18
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.